Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2026)

Neurocrine Biosciences has reported Operating Leases for 8 years, with the latest figure at $406.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 9.23% year-over-year to $406.2 million; the trailing twelve-month figure through Mar 2026 stood at $406.2 million (down 9.23% YoY), and the FY2025 full-year result was $415.3 million, down 8.75% from the prior year.
• Operating Leases for Q1 2026 stood at $406.2 million, down from $415.3 million in the prior quarter.
• The five-year high for Operating Leases was $489.8 million in Q2 2025, with the low at $85.9 million in Q3 2023.
• Historically, Operating Leases has averaged $262.3 million across 5 years, with a median of $286.2 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases declined 24.58% — and 2024, when it soared 233.18%.
• Neurocrine Biosciences' Operating Leases stood at $93.5 million in 2022, then surged by 102.99% to $189.8 million in 2023, then soared by 139.78% to $455.1 million in 2024, then dropped by 8.75% to $415.3 million in 2025, then dropped by 2.19% to $406.2 million in 2026.
• The last three Operating Leases figures came in at $406.2 million (Q1 2026), $415.3 million (Q4 2025), and $479.7 million (Q3 2025), per Business Quant data.